A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 984 participants.

Also called NCT04460885

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 984 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04460885
  • EudraCT 2020-000442-34
Other papers using this trial's data
  • Continuous glucose monitoring-based metrics and the duration of hypoglycaemia events with once-weekly insulin icodec versus once-daily insulin glargine U100 in insulin-naive type 2 diabetes: an exploratory analysis of ONWARDS 1 The lancet. Diabetes & endocrinology, 2024-11 DOI, PubMed 39374601
  • Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin The New England journal of medicine, 2023-07-27 DOI, PubMed 37356066

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Croatia, India, Israel, Italy, Japan, Mexico, Poland, Puerto Rico, Russia, Slovakia, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04460885. Randomized; no masking; primary purpose treatment. Start 2020-11-25 (actual); primary completion 2022-05-29 (actual). Results posted on 2025-06-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
Acronym
ONWARDS 1
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin icodec
Intervention (Drug)
Insulin glargine
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct04460885
Content hash
a6dc0a0641ea1dbd9e5db2164fefab82d12b2983a6ddb7079d39e82e9c1f698e